Zifi OZ Tablet is a combination antibiotic formulation containing Cefixime 200 mg and Ornidazole 500 mg, indicated for the treatment of mixed bacterial and protozoal infections. Cefixime, a third-generation cephalosporin, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, effective against various gram-positive and gram-negative pathogens. Ornidazole, a nitroimidazole derivative, targets anaerobic bacteria and protozoa by disrupting DNA synthesis, thereby exerting antiprotozoal and antibacterial effects. This synergistic combination is particularly useful in managing infections such as urinary tract infections, gastrointestinal infections including amoebiasis and giardiasis, respiratory tract infections, and pelvic inflammatory disease. Zifi OZ Tablet should be administered as prescribed by a healthcare professional, typically once or twice daily, with or without food. Caution is advised in patients with hypersensitivity to cephalosporins, nitroimidazoles, or any component of the formulation. Use during pregnancy and lactation should be under medical supervision. Common adverse effects may include gastrointestinal disturbances, headache, dizziness, and hypersensitivity reactions. It is essential to complete the full prescribed course to prevent resistance development and ensure therapeutic efficacy. Patients should inform their physician of any concurrent medications to avoid potential drug interactions.